By continuing to use our site, you agree to our Terms of Use and Privacy Policy. You can learn more about how we use cookies by reviewing our Privacy Policy.

I Agree


At Lumos Pharma, we believe that partnerships and collaborations are key to our everyday operations and valuable to our goal of developing therapeutics for rare diseases. We are actively seeking to expand our portfolio through acquisitions and in-licensing of pre-clinical and clinical-stage therapeutic candidates from others in the rare disease industry. Through strategic alliances with others who share our vision, we have the opportunity to maximize our contributions to science and to make a difference in the lives of patients who need it most.

For new partnership inquiries, please contact us.


Lumos Pharma’s lead therapeutic candidate, LUM-201, an oral growth hormone secretagogue with potential application in numerous disease indications is being advanced under license from Merck & Co. Prior development on the compound, including initial manufacturing, preclinical and significant clinical studies, had been completed by Merck prior to licensing.

We worked with Merck & Co. to develop ERVEBO® a vaccine for the prevention of disease caused by Zaire ebolavirus. Other key partners in the collaboration included the Biomedical Advanced Research and Development Authority (BARDA), the Defense Threat Reduction Agency (DTRA) and the original developer of the vaccine, the Public Health Agency of Canada (PHAC).

Licensed by Merck & Co.


We have entered into an exclusive worldwide license agreement with Ellipses Pharma Limited for the development of and rights to commercialize nanoparticle formulations of two therapeutics for oncology indications.